Which combination may increase the risk of myopathy when used with fenofibrate?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which combination may increase the risk of myopathy when used with fenofibrate?

When managing lipids, the combination of fenofibrate with a statin can raise the risk of muscle toxicity. Both drugs can cause myopathy on their own, and when used together, especially at high statin doses, their effects on muscle increase the chance of symptoms like weakness or pain and, in rare cases, rhabdomyolysis. This makes high-intensity statins the combination most likely to elevate myopathy risk with fenofibrate. Other drug classes listed do not have the same additive risk for myopathy with fenofibrate, so they’re not as concerning in this context. In practice, if a statin is needed, clinicians may opt for the lowest effective dose with careful monitoring, or consider alternatives such as ezetimibe or PCSK9 inhibitors. It’s also important to avoid using gemfibrozil with statins due to a much higher myopathy risk.

When managing lipids, the combination of fenofibrate with a statin can raise the risk of muscle toxicity. Both drugs can cause myopathy on their own, and when used together, especially at high statin doses, their effects on muscle increase the chance of symptoms like weakness or pain and, in rare cases, rhabdomyolysis. This makes high-intensity statins the combination most likely to elevate myopathy risk with fenofibrate.

Other drug classes listed do not have the same additive risk for myopathy with fenofibrate, so they’re not as concerning in this context. In practice, if a statin is needed, clinicians may opt for the lowest effective dose with careful monitoring, or consider alternatives such as ezetimibe or PCSK9 inhibitors. It’s also important to avoid using gemfibrozil with statins due to a much higher myopathy risk.

More practice questions